Cases & Deals

Share

Orphelia Pharma sells company to Orphalan

November 2025

Client(s) Orphelia Pharma

Jones Day advised Orphelia Pharma, a French pharmaceutical company dedicated to rare and serious pediatric diseases, particularly in neurology and oncology, and its shareholders in the sale of the company to Orphalan, a global pharmaceutical company specializing in the development and commercialization of orphan drugs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.